The positive effect of eugenol on acute pancreatic tissue injury: a rat experimental model.
Acute pancreatitis
eugenol
histopathological evaluation
immunohistochemistry
rat experimental model
Journal
The Pan African medical journal
ISSN: 1937-8688
Titre abrégé: Pan Afr Med J
Pays: Uganda
ID NLM: 101517926
Informations de publication
Date de publication:
2021
2021
Historique:
received:
29
08
2019
accepted:
20
01
2021
entrez:
29
4
2021
pubmed:
30
4
2021
medline:
5
5
2021
Statut:
epublish
Résumé
we present a rat experimental model used to evaluate the possible reduction in the extent of pancreatic tissue injury in acute pancreatitis cases, after administration of eugenol. one hundred and twenty Wistar rats were used, which were randomly assigned in 3 groups: sham (n=20), control (n=50) and eugenol (n=50). Acute pancreatitis was induced by biliopancreatic ligation in the control and eugenol groups, but not in the Sham group. In the eugenol group, eugenol was administered per-os. Five histopathological parameters, such as edema, inflammatory infiltration, duct dilatation, hemorrhage and acinar necrosis were evaluated. at 72 h from acute pancreatitis induction, the total histological score was diminished in the eugenol group (p<0.0005) and duct dilatation and inflammatory infiltration were reduced compared to the control group (p<0.05). In addition, at 72 h, eugenol reduced pancreatic myeloperoxidase activity (p<0.0005). eugenol, a highly free radical scavenger agent, may have a preventive role in acute pancreatic injury, as it was evident in our rat experimental model.
Identifiants
pubmed: 33912302
doi: 10.11604/pamj.2021.38.132.20202
pii: PAMJ-38-132
pmc: PMC8052617
doi:
Substances chimiques
Free Radical Scavengers
0
Eugenol
3T8H1794QW
Peroxidase
EC 1.11.1.7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
132Informations de copyright
Copyright: Alexandra Tsaroucha et al.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Free Radic Res. 1995 Dec;23(6):617-27
pubmed: 8574354
HPB Surg. 2016;2016:3203147
pubmed: 26884642
HPB (Oxford). 2006;8(4):264-86
pubmed: 18333137
Nat Prod Commun. 2010 Dec;5(12):1999-2006
pubmed: 21299140
Toxicology. 2010 Feb 9;268(3):204-12
pubmed: 20036707
Molecules. 2012 Jun 06;17(6):6953-81
pubmed: 22728369
Eur J Pharmacol. 2010 Feb 25;628(1-3):282-9
pubmed: 19958759
Int J Inflam. 2012;2012:360685
pubmed: 23304633
Pancreas. 2009 Jul;38(5):507-14
pubmed: 19346995
HPB (Oxford). 2012 Feb;14(2):73-81
pubmed: 22221567
Intractable Rare Dis Res. 2012 Aug;1(3):134-7
pubmed: 25343085
Int Immunopharmacol. 2015 May;26(1):265-71
pubmed: 25863235
J Surg Res. 2013 Jul;183(1):129-37
pubmed: 23273883
Mol Carcinog. 2010 Mar;49(3):290-301
pubmed: 20043298
Fundam Clin Pharmacol. 2011 Dec;25(6):708-16
pubmed: 21105912
Pancreas. 2006 Nov;33(4):323-30
pubmed: 17079934
Pancreas. 2016 May-Jun;45(5):633-40
pubmed: 27077712
J Hepatobiliary Pancreat Sci. 2010 Jan;17(1):24-36
pubmed: 20012328
Nat Prod Res. 2015;29(10):966-71
pubmed: 25229689
J Hepatobiliary Pancreat Sci. 2010 Jan;17(1):60-9
pubmed: 20012326
Appl Physiol Nutr Metab. 2017 Oct;42(10):1097-1105
pubmed: 28651060
Toxicology. 2002 Aug 1;177(1):39-54
pubmed: 12126794
Surg Clin North Am. 2007 Dec;87(6):1325-40, vii
pubmed: 18053834
Br Med Bull. 2004 Dec 13;71:1-11
pubmed: 15596865
Crit Care Med. 2010 Jul;38(7):1608-9
pubmed: 20562550
Int J Pancreatol. 1999 Jun;25(3):195-210
pubmed: 10453421
Br J Surg. 2006 Jun;93(6):738-44
pubmed: 16671062
J Hepatobiliary Pancreat Sci. 2010 Jan;17(1):45-52
pubmed: 20012652
Phytother Res. 2008 Oct;22(10):1361-6
pubmed: 18543354
Pancreatology. 2005;5(2-3):132-44
pubmed: 15849484
Cell Mol Gastroenterol Hepatol. 2017 Jun 10;4(2):251-262
pubmed: 28752114
Prostaglandins Leukot Essent Fatty Acids. 1993 May;48(5):363-72
pubmed: 8321872
Pharm Biol. 2015 Jul;53(7):968-74
pubmed: 25473818